State of the Art Update and Next Questions: Acute Myeloid Leukemia

The past decade has witnessed major advances in our comprehension of the biological heterogeneity of acute myeloid leukemia (AML); however, translating this knowledge into better outcomes for AML patients has lagged. Over the past year, two large, randomized phase III clinical trials with novel therapies produced positive results that are expected to lead to the first new drug approvals in AML in over 40 years.[1, 2] Many other promising drugs are currently under investigation, offering hope that even more novel treatments will be added to the armamentarium in the near future.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research